Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab and Lenalinomide Associated to Rituximab in Frontline DLBCL Patients ≥ 80 y/o
NCT04974216Phase 2Active, not recruiting
- Sponsor
- LYSARC
- Start
- Dec 2021
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of tafasitamab and lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by LYSARC. Primary endpoint: Overall Response Rate at 3 months. Started Dec 2021; status: active, not recruiting.
02
Drugs
tafasitamablenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04974216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04974216.